Idexx Laboratories price target lowered to $570 from $655 at Barclays

Barclays analyst Balaji Prasad lowered the firm’s price target on Idexx Laboratories to $570 from $655 and keeps an Overweight rating on the shares. The company’s Q1 report was a mixed bag with a lowered 2024 guide coupled with healthy Q1 metrics, the analyst tells investors in a research note.